Transcriptomic analysis reveals novel age-independent immunomodulatory proteins as a mode of cerebroprotection in P2X4 receptor knockout mice after ischemic stroke
Authors (first, second and last of 4)
Collection
Small molecules and biologics for future purinergic therapeutics
Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. This special
issue will focus on compounds or approaches that are either in clinical trials or headed in that
direction. It is intended to serve as an up-to-date description of efforts to discover and develop new small molecules and biologics as purinergic drugs.
Editors
-
Kenneth A. Jacobson
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
-
Daniela Salvemini
Saint Louis University School of Medicine, St. Louis, MO, USA
Articles (4 in this collection)
-
-
-
Activation of P2X4 receptors in midbrain cerebrospinal fluid-contacting nucleus leads to mechanical hyperalgesia in chronic constriction injury rats
Authors (first, second and last of 11)
-
Fluorescent A2A and A3 adenosine receptor antagonists as flow cytometry probes
Authors (first, second and last of 7)
